Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.

International Journal of Hematologic Oncology Pub Date : 2016-09-01 Epub Date: 2016-04-27 DOI:10.2217/ijh-2016-0001

Richard T Maziarz, Annie Guérin, Geneviève Gauthier, Julie Heroux, Maryia Zhdanava, Eric Q Wu, Simu K Thomas, Lei Chen

{"title":"Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.","authors":"Richard T Maziarz, Annie Guérin, Geneviève Gauthier, Julie Heroux, Maryia Zhdanava, Eric Q Wu, Simu K Thomas, Lei Chen","doi":"10.2217/ijh-2016-0001","DOIUrl":null,"url":null,"abstract":"Aim: To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large US administrative databases.Patients & methods: Among the 209 patients with acute lymphoblastic leukemia, HRU and costs were described over the up to 5 years after the HSCT.Results: HRU and costs following the HSCTs were substantial. The highest average costs and most intensive HRU were observed within the first year following the HSCTs (49 outpatient visits; 29 laboratory service visits; 68 inpatient days), with a first year cost of US$683,099 and substantial costs over the following years.Conclusion: HRU and direct costs associated with allogeneic HSCTs are substantial.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2016-0001","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hematologic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/ijh-2016-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/4/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 7

Abstract

Aim: To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large US administrative databases.

Patients & methods: Among the 209 patients with acute lymphoblastic leukemia, HRU and costs were described over the up to 5 years after the HSCT.

Results: HRU and costs following the HSCTs were substantial. The highest average costs and most intensive HRU were observed within the first year following the HSCTs (49 outpatient visits; 29 laboratory service visits; 68 inpatient days), with a first year cost of US$683,099 and substantial costs over the following years.

Conclusion: HRU and direct costs associated with allogeneic HSCTs are substantial.

Abstract Image

查看原文本刊更多论文

急性淋巴细胞白血病儿童患者接受同种异体干细胞移植的5年直接成本。

目的:利用美国两个大型行政数据库的数据，评估急性淋巴细胞白血病儿童患者同种异体造血干细胞移植(hsct)后的5年医疗资源利用率(HRU)和直接付款人成本。患者和方法:在209例急性淋巴细胞白血病患者中，描述了HSCT后长达5年的HRU和成本。结果:hsct后的HRU和费用是可观的。最高的平均费用和最密集的HRU是在hsct后的第一年观察到的(49次门诊就诊;29次实验室服务访问;68个住院日)，第一年费用为683,099美元，随后几年费用不菲。结论:与同种异体造血干细胞移植相关的HRU和直接成本是巨大的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hematologic Oncology

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Hematologic Oncology welcomes unsolicited article proposals. Email us today to discuss the suitability of your research and our options for authors, including Accelerated Publication. Find out more about publishing open access with us here.